Cited by 65

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Interferon regulatory factor 8/interferon consensus sequence binding protein is a critical transcription factor for the physiological phenotype of microglia

Horiuchi, Makoto, Wakayama, Kouji, Itoh, Aki, Kawai, Kumi, Pleasure, David, Ozato, Keiko, Itoh, Takayuki·2012·Journal of Neuroinflammation

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1742-2094-9-227

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 IRF8-deficient microglia colonized the CNS normally, but could not be identified by AIF1/IBA1 immunoreactivity. The spinal cords obtained from adult Irf8+/+ and Irf8-/- mice were immunolabeled for various microglial markers (A), and positive cells in the dorsal column at the Th1 spinal level were quantified (B). Microglia were reliably identified as CD11b and PU.1 double positive cells in both Irf8+/+ and Irf8-/- CNS tissues (pink arrows in far left panels in A). Note that few Irf8-/- microglia demonstrated detectable immunoreactivity for AIF1/IBA1. Scale bar: 100 μm. **P < 0.01. (C) 20 μm-thick z-stack confocal images of the microglia immunolabeled for CD11b (green) and PU.1 (red) in the dorsal columns at the Th1 spinal level. CD11b-positive microglial processes were much sparser in the dorsal column of Irf8-/- mice than those in Irf8+/+ mice, and processes of Irf8-/- microglia were thicker and less elaborated than those of Irf8+/+ microglia. PU.1-positive microglial nuclei are indicated by arrows, demonstrating that similar numbers of microglia are distributed in the Irf8+/+ and Irf8-/- spinal cords in contrast to the different density of the microglial processes. Scale bar: 100 μm.
Figure 1 IRF8-deficient microglia colonized the CNS normally, but could not be identified by AIF1/IBA1 immunoreactivity. The spinal cords obtained from adult Irf8+/+ and Irf8-/- mice were immunolabeled for various microglial markers (A), and positive cells in the dorsal column at the Th1 spinal level were quantified (B). Microglia were reliably identified as CD11b and PU.1 double positive cells in both Irf8+/+ and Irf8-/- CNS tissues (pink arrows in far left panels in A). Note that few Irf8-/- microglia demonstrated detectable immunoreactivity for AIF1/IBA1. Scale bar: 100 μm. **P < 0.01. (C) 20 μm-thick z-stack confocal images of the microglia immunolabeled for CD11b (green) and PU.1 (red) in the dorsal columns at the Th1 spinal level. CD11b-positive microglial processes were much sparser in the dorsal column of Irf8-/- mice than those in Irf8+/+ mice, and processes of Irf8-/- microglia were thicker and less elaborated than those of Irf8+/+ microglia. PU.1-positive microglial nuclei are indicated by arrows, demonstrating that similar numbers of microglia are distributed in the Irf8+/+ and Irf8-/- spinal cords in contrast to the different density of the microglial processes. Scale bar: 100 μm.CC BY · PubMed Central
Figure 2 Irf8-/- CNS tissues contain significantly less microglial processes than Irf8+/+ tissues. (A) Dorsal columns at the Th1 spinal level were immunolabeled for CD11b and PU.1, and inverted confocal fluorescence images of 12 μm-thick transverse sections are shown in monochrome. Only cross-sectional areas of the dorsal columns are shown. The location of each microglial nucleus positive for PU.1 is indicated by a circle to demonstrate similar distributions of microglia between the Irf8+/+ and Irf8-/- dorsal columns, which contrasts to lower densities of CD11b-positive microglial processes in Irf8-/- mice than in Irf8+/+ mice. (B) Similar difference was observed in the coronal sections of the corpus callosum. (C) The percentages of CD11b-positive areas in the whole cross-sectional area of the dorsal column were measured and compared quantitatively between Irf8-/- (closed bar) and Irf8+/+ mice (open bar). Three 3-month-old animals were used in each genotype. **P < 0.01. Scale bar: 100 μm.
Figure 2 Irf8-/- CNS tissues contain significantly less microglial processes than Irf8+/+ tissues. (A) Dorsal columns at the Th1 spinal level were immunolabeled for CD11b and PU.1, and inverted confocal fluorescence images of 12 μm-thick transverse sections are shown in monochrome. Only cross-sectional areas of the dorsal columns are shown. The location of each microglial nucleus positive for PU.1 is indicated by a circle to demonstrate similar distributions of microglia between the Irf8+/+ and Irf8-/- dorsal columns, which contrasts to lower densities of CD11b-positive microglial processes in Irf8-/- mice than in Irf8+/+ mice. (B) Similar difference was observed in the coronal sections of the corpus callosum. (C) The percentages of CD11b-positive areas in the whole cross-sectional area of the dorsal column were measured and compared quantitatively between Irf8-/- (closed bar) and Irf8+/+ mice (open bar). Three 3-month-old animals were used in each genotype. **P < 0.01. Scale bar: 100 μm.CC BY · PubMed Central
Figure 3 IRF8-deficient microglia in the mixed glial cultures exhibited a hyperproliferative phenotype in response to M-CSF and GM-CSF. A-I, Phase contrast images of mixed glial cultures from Irf8+/+ (A-C), Irf8+/- (D-F), and Irf8-/- (G-I) brain tissues. Cells were transferred to medium alone (control), medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) at 5 days in vitro, and then maintained in the same medium for another 4 days. Most microglia were seen as phase-bright round cells on the sheet of flat glial cells. Scale Bar: 50 μm. (J-K) Percentages of EdU-positive cells in total CD11b+ (J) or CD11b- (K) cells in the mixed glial cultures of the respective genotypes. Cells treated medium alone (cont), or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 4 days were exposed to EdU at 6 hours prior to fixation, and double-stained for CD11b and EdU. **P < 0.01 and N.S indicates no significant difference in a comparison of the two groups indicated.
Figure 3 IRF8-deficient microglia in the mixed glial cultures exhibited a hyperproliferative phenotype in response to M-CSF and GM-CSF. A-I, Phase contrast images of mixed glial cultures from Irf8+/+ (A-C), Irf8+/- (D-F), and Irf8-/- (G-I) brain tissues. Cells were transferred to medium alone (control), medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) at 5 days in vitro, and then maintained in the same medium for another 4 days. Most microglia were seen as phase-bright round cells on the sheet of flat glial cells. Scale Bar: 50 μm. (J-K) Percentages of EdU-positive cells in total CD11b+ (J) or CD11b- (K) cells in the mixed glial cultures of the respective genotypes. Cells treated medium alone (cont), or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 4 days were exposed to EdU at 6 hours prior to fixation, and double-stained for CD11b and EdU. **P < 0.01 and N.S indicates no significant difference in a comparison of the two groups indicated.CC BY · PubMed Central
Figure 4 F4/80, CD11c, and Ly-6G expression in Irf8+/+ and Irf8-/- microglia in the mixed glial cultures maintained in the presence of M-CSF or GM-CSF. Mixed glial cells were cultured in medium alone (control) or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 4 days, and labeled with anti-CD45 and anti-CD11b antibodies in combination with each of anti-F4/80, anti-CD11c or anti-Ly-6G antibodies. The bivariate plots show expression of CD11b, F4/80, CD11c and Ly-6G on gated CD45-positive cells. The quadrants were set using corresponding isotype controls.
Figure 4 F4/80, CD11c, and Ly-6G expression in Irf8+/+ and Irf8-/- microglia in the mixed glial cultures maintained in the presence of M-CSF or GM-CSF. Mixed glial cells were cultured in medium alone (control) or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 4 days, and labeled with anti-CD45 and anti-CD11b antibodies in combination with each of anti-F4/80, anti-CD11c or anti-Ly-6G antibodies. The bivariate plots show expression of CD11b, F4/80, CD11c and Ly-6G on gated CD45-positive cells. The quadrants were set using corresponding isotype controls.CC BY · PubMed Central
Figure 5 Purified Irf8+/+ and Irf8-/- microglia in vitro. (A-D) Representative phase contrast (A, B) and immunocytochemical (C, D) pictures of the microglia isolated from the Irf8+/+ (A, C) and Irf8-/- (B, D) mixed glial cultures grown in the presence of M-CSF (20 ng/ml) by magnetic-activated cell sorting. Purified cells were immunolabeled for CD11b (green in C, D) at 24 h after isolation. Nuclei were counterstained with DAPI (blue). Scale Bar: 50 μm. (E)IRF8 and PU.1/SFPI1 mRNA levels in the purified Irf8+/+ microglia. Purified microglia were incubated in medium alone (control) or in the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both for 24 h. Reverse transcribed IRF8 and PU.1/SFPI1 cDNA levels are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. (F) Immunoblots for IRF8 confirmed the results of mRNA. (G) Purified Irf8-/- CD11b+ microglia were less proliferative than Irf8+/+ CD11b+ microglia even in the presence of exogenous M-CSF. Purified microglia were preincubated with medium alone for 24 h after isolation from Irf8+/+ (open bars) and Irf8-/- (closed bars) mixed glial cultures, and then treated with medium alone (control), or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 24 h. After a 6 hour incubation with EdU, EdU-positive and DAPI-positive nuclei were counted. **P < 0.01 in comparison with control or between the two groups indicated.
Figure 5 Purified Irf8+/+ and Irf8-/- microglia in vitro. (A-D) Representative phase contrast (A, B) and immunocytochemical (C, D) pictures of the microglia isolated from the Irf8+/+ (A, C) and Irf8-/- (B, D) mixed glial cultures grown in the presence of M-CSF (20 ng/ml) by magnetic-activated cell sorting. Purified cells were immunolabeled for CD11b (green in C, D) at 24 h after isolation. Nuclei were counterstained with DAPI (blue). Scale Bar: 50 μm. (E)IRF8 and PU.1/SFPI1 mRNA levels in the purified Irf8+/+ microglia. Purified microglia were incubated in medium alone (control) or in the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both for 24 h. Reverse transcribed IRF8 and PU.1/SFPI1 cDNA levels are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. (F) Immunoblots for IRF8 confirmed the results of mRNA. (G) Purified Irf8-/- CD11b+ microglia were less proliferative than Irf8+/+ CD11b+ microglia even in the presence of exogenous M-CSF. Purified microglia were preincubated with medium alone for 24 h after isolation from Irf8+/+ (open bars) and Irf8-/- (closed bars) mixed glial cultures, and then treated with medium alone (control), or medium supplemented with M-CSF (20 ng/ml) or GM-CSF (20 ng/ml) for 24 h. After a 6 hour incubation with EdU, EdU-positive and DAPI-positive nuclei were counted. **P < 0.01 in comparison with control or between the two groups indicated.CC BY · PubMed Central
Figure 6 IRF8-deficient microglia demonstrated a reduced phagocytic capacity in vitro. Microglia from Irf8+/+ (A) and Irf8-/- (B) mice were incubated with Alexa Fluor™ 488-conjugated zymosan particles for 24 hours. Scale bar: 50 μm. (C-D) Percentages of Alexa Fluor™ 488-positive cells in total cells (C) and mean fluorescent intensity (MFI) of Alexa Fluor™ 488-positive cells (D) were measured in Irf8+/+, Irf8+/-, and Irf8-/- microglial cultures at 0, 1, 6, and 24 hour after adding the zymosan particles. The MFI of a non-phagocytosed Alexa Fluor™ 488-conjugated zymosan particle is also shown (Zymosan- Alexa488) in D. **P < 0.001 in comparison with the two groups indicated.
Figure 6 IRF8-deficient microglia demonstrated a reduced phagocytic capacity in vitro. Microglia from Irf8+/+ (A) and Irf8-/- (B) mice were incubated with Alexa Fluor™ 488-conjugated zymosan particles for 24 hours. Scale bar: 50 μm. (C-D) Percentages of Alexa Fluor™ 488-positive cells in total cells (C) and mean fluorescent intensity (MFI) of Alexa Fluor™ 488-positive cells (D) were measured in Irf8+/+, Irf8+/-, and Irf8-/- microglial cultures at 0, 1, 6, and 24 hour after adding the zymosan particles. The MFI of a non-phagocytosed Alexa Fluor™ 488-conjugated zymosan particle is also shown (Zymosan- Alexa488) in D. **P < 0.001 in comparison with the two groups indicated.CC BY · PubMed Central
Figure 7 AIF1/IBA1 expression in Irf8-/- microglia was reduced but still inducible by IFNγ. (A) Quantitative and kinetic analysis of AIF1/IBA1 mRNA in Irf8+/+ and Irf8-/- microglia after addition of medium alone (Control, open circle), IFNγ (IFNG, 100 ng/ml, closed circle), lipopolysaccharide (LPS, 100 ng/ml, open square) or both (closed square). Reverse transcribed cDNA levels at the indicated time points were quantified by qPCR and are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. Data were from at least three independent experiments. At time 0, data from controls are only shown. (B) Irf8-/- microglia expressed far less AIF1/IBA1 protein than Irf8+/+ microglia. Purified microglia were maintained in the medium containing IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both for 24 h. Subsequent immunoblots for β-actin (ACTB) are shown for equal protein loading.
Figure 7 AIF1/IBA1 expression in Irf8-/- microglia was reduced but still inducible by IFNγ. (A) Quantitative and kinetic analysis of AIF1/IBA1 mRNA in Irf8+/+ and Irf8-/- microglia after addition of medium alone (Control, open circle), IFNγ (IFNG, 100 ng/ml, closed circle), lipopolysaccharide (LPS, 100 ng/ml, open square) or both (closed square). Reverse transcribed cDNA levels at the indicated time points were quantified by qPCR and are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. Data were from at least three independent experiments. At time 0, data from controls are only shown. (B) Irf8-/- microglia expressed far less AIF1/IBA1 protein than Irf8+/+ microglia. Purified microglia were maintained in the medium containing IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both for 24 h. Subsequent immunoblots for β-actin (ACTB) are shown for equal protein loading.CC BY · PubMed Central
Figure 8 Kinetics of IFNB1 (A) and IL12B (B) mRNA levels in Irf8+/+ and Irf8-/- microglia after the exposure to IFNγ and lipopolysaccharide. Purified microglia were incubated in medium alone (Control, closed and open circle in the left panels) or in the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both (IFNG + LPS) for 24 h. IFNB1 and IL12B mRNA at the indicated time points were quantified by qPCR and are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. Data were calculated from at least three independent experiments in each genotype. At time 0, data from controls are only shown. **P < 0.01 and *P < 0.05, in a comparison of the two genotypes at the indicated time points.
Figure 8 Kinetics of IFNB1 (A) and IL12B (B) mRNA levels in Irf8+/+ and Irf8-/- microglia after the exposure to IFNγ and lipopolysaccharide. Purified microglia were incubated in medium alone (Control, closed and open circle in the left panels) or in the presence of IFNγ (IFNG, 100 ng/ml), lipopolysaccharide (LPS, 100 ng/ml) or both (IFNG + LPS) for 24 h. IFNB1 and IL12B mRNA at the indicated time points were quantified by qPCR and are plotted as ratios to copy numbers of β-actin cDNA on a logarithmic scale. Data were calculated from at least three independent experiments in each genotype. At time 0, data from controls are only shown. **P < 0.01 and *P < 0.05, in a comparison of the two genotypes at the indicated time points.CC BY · PubMed Central
Figure 9 A defective phenotype of IRF8-deficient microglia in vivo in the cuprizone-induced demyelination model. (A) There was no quantitative difference in corpus callosal microglia, myelinating oligodendrocytes, and NG2-positive oligodendroglial precursor cells between Irf8+/+ and Irf8-/- mice before cuprizone feeding. Microglia and myelinating oligodendrocytes were identified by immunoreactivity for nuclear PU.1 and for the cytosolic CC1 epitope, respectively. (B) Cuprizone-mediated demyelination in the medial corpus callosum in Irf8+/+ and Irf8-/- mice. Representative LFB-PAS-stained paraffin sections of the medial corpus callosi of Irf8+/+ and Irf8-/- mice at 4 and 6 weeks of cuprizone diet (left panel). Scale bar: 100 μm. Reduction of myelinating oligodendrocytes in the corpus callosum. CC1+ oligodendrocytes per unit area of 6 μm-thick coronal sections were counted. At least three mice were used for each data point (right graph). (C) Microglial accumulation in the corpus callosum was delayed in Irf8-/- mice compared with Irf8+/+ mice. CD11b+ microglia with PU.1+ nuclei were quantified in 6 μm-thick coronal sections as in B (right graph). Note that the abnormal oval cell shape of activated Irf8-/- microglia at 6 weeks of cuprizone feeding. Scale bar: 100 μm. (D) Oil red O plus hematoxylin staining of the corpus callosum of Irf8+/+ and Irf8-/- mice at 0, 4 and 6 weeks of cuprizone feeding. Lipid-rich myelin debris visualized by Oil red O staining (red arrows) rapidly accumulated in the corpus callosum of Irf8-/- mice, as demyelination progressed. Scale bar: 25 μm. Data are presented as mean ± standard error. *P < 0.05 by Mann-Whitney U test.
Figure 9 A defective phenotype of IRF8-deficient microglia in vivo in the cuprizone-induced demyelination model. (A) There was no quantitative difference in corpus callosal microglia, myelinating oligodendrocytes, and NG2-positive oligodendroglial precursor cells between Irf8+/+ and Irf8-/- mice before cuprizone feeding. Microglia and myelinating oligodendrocytes were identified by immunoreactivity for nuclear PU.1 and for the cytosolic CC1 epitope, respectively. (B) Cuprizone-mediated demyelination in the medial corpus callosum in Irf8+/+ and Irf8-/- mice. Representative LFB-PAS-stained paraffin sections of the medial corpus callosi of Irf8+/+ and Irf8-/- mice at 4 and 6 weeks of cuprizone diet (left panel). Scale bar: 100 μm. Reduction of myelinating oligodendrocytes in the corpus callosum. CC1+ oligodendrocytes per unit area of 6 μm-thick coronal sections were counted. At least three mice were used for each data point (right graph). (C) Microglial accumulation in the corpus callosum was delayed in Irf8-/- mice compared with Irf8+/+ mice. CD11b+ microglia with PU.1+ nuclei were quantified in 6 μm-thick coronal sections as in B (right graph). Note that the abnormal oval cell shape of activated Irf8-/- microglia at 6 weeks of cuprizone feeding. Scale bar: 100 μm. (D) Oil red O plus hematoxylin staining of the corpus callosum of Irf8+/+ and Irf8-/- mice at 0, 4 and 6 weeks of cuprizone feeding. Lipid-rich myelin debris visualized by Oil red O staining (red arrows) rapidly accumulated in the corpus callosum of Irf8-/- mice, as demyelination progressed. Scale bar: 25 μm. Data are presented as mean ± standard error. *P < 0.05 by Mann-Whitney U test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 53

  1. Prinz M, Mildner A: Microglia in the CNS: immigrants from another world. Glia 2011, 59:177–187. · DOI
  2. Ransohoff RM, Cardona AE: The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253–262. · DOI · Paper page
  3. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM: Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007, 10:1538–1543. · DOI · Paper page
  4. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M: Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841–845. · DOI · Paper page
  5. Ozato K, Tailor P, Kubota T: The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 2007, 282:20065–20069. · DOI
  6. Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:535–584. · DOI · Paper page
  7. Wang H, Morse HC 3rd: IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol Res 2009, 43:109–117. · DOI
  8. Fehr T, Schoedon G, Odermatt B, Holtschke T, Schneemann M, Bachmann MF, Mak TW, Horak I, Zinkernagel RM: Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. J Exp Med 1997, 185:921–931. · DOI · Paper page
  9. Ellis SL, Gysbers V, Manders PM, Li W, Hofer MJ, Müller M, Campbell IL: The cell-specific induction of CXC chemokine ligand 9 mediated by IFN-γ in microglia of the central nervous system is determined by the myeloid transcription factor PU.1. J Immunol 2010, 185:1864–1877. · DOI
  10. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, Inoue K: IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep 2012, 1:334–340. · DOI · Paper page
  11. Horiuchi M, Itoh A, Pleasure D, Itoh T: MEK-ERK signaling is involved in interferon-γ-induced death of oligodendroglial progenitor cells. J Biol Chem 2006, 281:20095–20106. · DOI
  12. Kawai K, Itoh T, Itoh A, Horiuchi M, Wakayama K, Bannerman P, Garbern JY, Pleasure D, Lindsten T: Maintenance of the relative proportion of oligodendrocytes to axons even in the absence of BAX and BAK. Eur J Neurosci 2009, 30:2030–2041. · DOI · Paper page
  13. Suzumura A, Mezitis SG, Gonatas NK, Silberberg DH: MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. J Neuroimmunol 1987, 15:263–278. · DOI
  14. Scheller M, Foerster J, Heyworth CM, Waring JF, Löhler J, Gilmore GL, Shadduck RK, Dexter TM, Horak I: Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 1999, 94:3764–3771. · DOI · Paper page
  15. Horiuchi M, Lindsten T, Pleasure D, Itoh T: Differing in vivo survival dependency of mouse and rat NG2+ oligodendroglial progenitor cells. J Neurosci Res 2010, 88:957–970. · DOI
  16. Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK, Millard PJ, Mao F, Leung WY, Haugland RP: Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J Histochem Cytochem 1999, 47:1179–1188. · DOI
  17. Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K: Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med 1997, 186:1523–1534. · DOI · Paper page
  18. Li P, Wong JJ, Sum C, Sin WX, Ng KQ, Koh MB, Chin KC: IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes. Blood 2011, 117:2847–2854. · DOI · Paper page
  19. Kondo A, Nakano T, Suzuki K: Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res 1987, 425:186–190. · DOI · Paper page
  20. McMahon EJ, Suzuki K, Matsushima GK: Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 2002, 130:32–45. · DOI · Paper page
  21. Remington LT, Babcock AA, Zehntner SP, Owens T: Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 2007, 170:1713–1724. · DOI · Paper page
  22. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA: Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996, 15:5647–5658. · DOI · Paper page
  23. Dalmau I, Vela JM, González B, Finsen B, Castellano B: Dynamics of microglia in the developing rat brain. J Comp Neurol 2003, 458:144–157. · DOI
  24. Cohen PE, Zhu L, Nishimura K, Pollard JW: Colony-stimulating factor 1 regulation of neuroendocrine pathways that control gonadal function in mice. Endocrinology 2002, 143:1413–1422. · DOI
  25. Wegiel J, Wisniewski HM, Dziewiatkowski J, Tarnawski M, Kozielski R, Trenkner E, Wiktor-Jedrzejczak W: Reduced number and altered morphology of microglial cells in colony stimulating factor-1-deficient osteopetrotic op/op mice. Brain Res 1998, 804:135–139. · DOI
  26. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314–1318. · DOI · Paper page
  27. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J: Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 2009, 29:3974–3980. · DOI · Paper page
  28. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB: ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752–758. · DOI · Paper page
  29. Hines DJ, Hines RM, Mulligan SJ, Macvicar BA: Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 2009, 57:1610–1618. · DOI
  30. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S: Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci 2000, 113:3073–3084. · DOI
  31. Heinrich V, Lee CY: Blurred line between chemotactic chase and phagocytic consumption: an immunophysical single-cell perspective. J Cell Sci 2011, 124:3041–3051. · DOI
  32. Schulze JO, Quedenau C, Roske Y, Adam T, Schüler H, Behlke J, Turnbull AP, Sievert V, Scheich C, Mueller U, Heinemann U, Büssow K: Structural and functional characterization of human Iba proteins. FEBS J 2008, 275:4627–4640. · DOI
  33. Sibinga NE, Feinberg MW, Yang H, Werner F, Jain MK: Macrophage-restricted and interferon γ-inducible expression of the allograft inflammatory factor-1 gene requires Pu.1. J Biol Chem 2002, 277:16202–16210. · DOI
  34. Kinchen JM, Ravichandran KS: Phagosome maturation: going through the acid test. Nat Rev Mol Cell Biol 2008, 9:781–795. · DOI · Paper page
  35. Dissing-Olesen L, Ladeby R, Nielsen HH, Toft-Hansen H, Dalmau I, Finsen B: Axonal lesion-induced microglial proliferation and microglial cluster formation in the mouse. Neuroscience 2007, 149:112–122. · DOI
  36. Graeber MB, López-Redondo F, Ikoma E, Ishikawa M, Imai Y, Nakajima K, Kreutzberg GW, Kohsaka S: The microglia/macrophage response in the neonatal rat facial nucleus following axotomy. Brain Res 1998, 813:241–253. · DOI
  37. Raivich G, Moreno-Flores MT, Möller JC, Kreutzberg GW: Inhibition of posttraumatic microglial proliferation in a genetic model of macrophage colony-stimulating factor deficiency in the mouse. Eur J Neurosci 1994, 6:1615–1618. · DOI
  38. Yamamoto S, Nakajima K, Kohsaka S: Macrophage-colony stimulating factor as an inducer of microglial proliferation in axotomized rat facial nucleus. J Neurochem 2010, 115:1057–1067. · DOI
  39. Giulian D, Ingleman JE: Colony-stimulating factors as promoters of ameboid microglia. J Neurosci 1988, 8:4707–4717. · DOI
  40. Ganter S, Northoff H, Männel D, Gebicke-Härter PJ: Growth control of cultured microglia. J Neurosci Res 1992, 33:218–230. · DOI
  41. Ringheim GE: Mitogenic effects of interleukin-5 on microglia. Neurosci Lett 1995, 201:131–134. · DOI
  42. Suzumura A, Sawada M, Yamamoto H, Marunouchi T: Effects of colony stimulating factors on isolated microglia in vitro. J Neuroimmunol 1990, 30:111–120. · DOI
  43. Suzumura A, Sawada M, Itoh Y, Marunouchi T: Interleukin-4 induces proliferation and activation of microglia but suppresses their induction of class II major histocompatibility complex antigen expression. J Neuroimmunol 1994, 53:209–218. · DOI
  44. Blevins G, Fedoroff S: Microglia in colony-stimulating factor 1-deficient op/op mice. J Neurosci Res 1995, 40:535–544. · DOI
  45. Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Stern LJ, Strominger JL, Riese R: Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001, 98:6295–6300. · DOI
  46. Ponomarev ED, Novikova M, Maresz K, Shriver LP, Dittel BN: Development of a culture system that supports adult microglial cell proliferation and maintenance in the resting state. J Immunol Methods 2005, 300:32–46. · DOI
  47. Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K: ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood 2003, 102:4547–4554. · DOI
  48. Zhu C, Saberwal G, Lu Y, Platanias LC, Eklund EA: The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem 2004, 279:50874–50885. · DOI · Paper page
  49. Gabriele L, Ozato K: The role of the interferon regulatory factor (IRF) family in dendritic cell development and function. Cytokine Growth Factor Rev 2007, 18:503–510. · DOI
  50. Donnou S, Fisson S, Mahe D, Montoni A, Couez D: Identification of new CNS-resident macrophage subpopulation molecular markers for the discrimination with murine systemic macrophages. J Neuroimmunol 2005, 169:39–49. · DOI
  51. Schmid CD, Melchior B, Masek K, Puntambekar SS, Danielson PE, Lo DD, Sutcliffe JG, Carson MJ: Differential gene expression in LPS/IFNγ activated microglia and macrophages: in vitro versus in vivo. J Neurochem 2009, 1:117–125. · DOI
  52. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, International MS Genetics C, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR: Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009, 41:776–782. · DOI · Paper page
  53. Hambleton S, Salem S, Bustamante J, et al.: IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011, 365:127–138. · DOI

Cited by

Sorted by citations

Metadata

Authors
Horiuchi, M., Wakayama, K., Itoh, A., Kawai, K., Pleasure, D., Ozato, K., & Itoh, T.
Venue
Journal of Neuroinflammation
Published
2012-09-28
Volume
9
Issue
1
ISSN
1742-2094
Cited by
65
References
15
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review